Does the media prefer MNPR or HUMA?

In the previous week, Monopar Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 7 mentions for Monopar Therapeutics and 6 mentions for Humacyte. Monopar Therapeutics' average media sentiment score of 0.42 beat Humacyte's score of 0.26 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, HUMA or SVA?

Humacyte has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 71.02 -$40.83M -$0.49 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Which has higher earnings and valuation, HUMA or NGNE?

Humacyte has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 71.02 -$40.83M -$0.49 N/A Neurogene $930K 551.89 -$90.35M -$5.03 N/A

Is HUMA or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Neurogene's return on equity of -45.10% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,556.29% -983.32% -88.84% Neurogene N/A -45.10% -41.00%

Does the media favor HUMA or NGNE?

In the previous week, Humacyte had 3 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Humacyte and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.67 beat Humacyte's score of 0.26 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, HUMA or ALT?

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 71.02 -$40.83M -$0.49 N/A Altimmune $40K 13,275.99 -$88.09M -$0.78 N/A

Is HUMA or ALT more profitable?

Altimmune has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Altimmune's return on equity of -31.41% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,556.29% -983.32% -88.84% Altimmune N/A -31.41% -26.96%

Does the media favor HUMA or ALT?

In the previous week, Humacyte had 2 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Humacyte and 4 mentions for Altimmune. Humacyte's average media sentiment score of 0.26 beat Altimmune's score of 0.02 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CBIO or HUMA?

In the previous week, Humacyte had 4 more articles in the media than Crescent Biopharma. MarketBeat recorded 6 mentions for Humacyte and 2 mentions for Crescent Biopharma. Humacyte's average media sentiment score of 0.26 beat Crescent Biopharma's score of 0.25 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Humacyte (HUMA) Competitors

$0.52 +0.02 (+3.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-1.05%)

As of 10/2/2026 07:55 PM Eastern

Compare

HUMA vs. MNPR, SVA, NGNE, ALT, and CBIO

Should you buy Humacyte stock or one of its competitors? Humacyte's main competitors and comparable companies include Monopar Therapeutics (MNPR), Sinovac Biotech (SVA), Neurogene (NGNE), Altimmune (ALT), and Crescent Biopharma (CBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Humacyte compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Monopar Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 7 mentions for Monopar Therapeutics and 6 mentions for Humacyte. Monopar Therapeutics' average media sentiment score of 0.42 beat Humacyte's score of 0.26 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics has higher earnings, but lower revenue than Humacyte. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A

Monopar Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Monopar Therapeutics' return on equity of -13.08% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Humacyte	-4,556.29%	-983.32%	-88.84%

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Monopar Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Monopar Therapeutics currently has a consensus price target of $122.00, suggesting a potential upside of 56.47%. Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,154.39%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Monopar Therapeutics beats Humacyte on 9 of the 15 factors compared between the two stocks.

How does Humacyte compare to Sinovac Biotech?

Humacyte (NASDAQ:HUMA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Humacyte has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Humacyte presently has a consensus price target of $6.54, indicating a potential upside of 1,154.39%. Sinovac Biotech has a consensus price target of $1.00, indicating a potential downside of 84.54%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Sinovac Biotech has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Sinovac Biotech's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Sinovac Biotech	N/A	N/A	N/A

Humacyte has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Humacyte had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Humacyte and 0 mentions for Sinovac Biotech. Humacyte's average media sentiment score of 0.26 beat Sinovac Biotech's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Neutral
Sinovac Biotech	Neutral

Summary

Humacyte beats Sinovac Biotech on 8 of the 14 factors compared between the two stocks.

How does Humacyte compare to Neurogene?

Humacyte (NASDAQ:HUMA) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Humacyte has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

Humacyte has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Humacyte currently has a consensus target price of $6.54, indicating a potential upside of 1,154.39%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 226.19%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Humacyte had 3 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Humacyte and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.67 beat Humacyte's score of 0.26 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.7% of Humacyte shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Neurogene's return on equity of -45.10% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Neurogene	N/A	-45.10%	-41.00%

Summary

Neurogene beats Humacyte on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to Altimmune?

Humacyte (NASDAQ:HUMA) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Altimmune has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Altimmune's return on equity of -31.41% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Altimmune	N/A	-31.41%	-26.96%

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A
Altimmune	$40K	13,275.99	-$88.09M	-$0.78	N/A

Humacyte has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Humacyte currently has a consensus target price of $6.54, suggesting a potential upside of 1,154.39%. Altimmune has a consensus target price of $14.33, suggesting a potential upside of 425.03%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Humacyte is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Humacyte had 2 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Humacyte and 4 mentions for Altimmune. Humacyte's average media sentiment score of 0.26 beat Altimmune's score of 0.02 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Humacyte beats Altimmune on 10 of the 16 factors compared between the two stocks.

How does Humacyte compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Crescent Biopharma has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

In the previous week, Humacyte had 4 more articles in the media than Crescent Biopharma. MarketBeat recorded 6 mentions for Humacyte and 2 mentions for Crescent Biopharma. Humacyte's average media sentiment score of 0.26 beat Crescent Biopharma's score of 0.25 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Crescent Biopharma's return on equity of -101.50% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Humacyte	-4,556.29%	-983.32%	-88.84%

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Humacyte has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	49.06	-$153.94M	-$6.72	N/A
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A

Crescent Biopharma currently has a consensus price target of $29.60, indicating a potential upside of 106.70%. Humacyte has a consensus price target of $6.54, indicating a potential upside of 1,154.39%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Humacyte beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$139.71M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-1.06	13.06	275.68	26.04
Price / Sales	71.02	1,373.91	658.18	100.99
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	26.08	16.63	10.93	6.31
Net Income	-$40.83M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-6.42%	-2.99%	-2.01%	-1.66%
1 Month Performance	-12.50%	-10.60%	-6.15%	-4.50%
1 Year Performance	-75.17%	19.44%	7.44%	2.06%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	2.2494 of 5 stars	$0.52 +3.7%	$6.54 +1,154.4%	-70.9%	$139.71M	$2.04M	N/A	184
MNPR Monopar Therapeutics	2.9386 of 5 stars	$95.72 -0.8%	$120.08 +25.5%	-19.8%	$647.52M	N/A	N/A	22	News Coverage
SVA Sinovac Biotech	0.8641 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.66M	$386.01M	N/A	3,008	High Trading Volume
NGNE Neurogene	2.8128 of 5 stars	$32.57 +1.5%	$83.67 +156.9%	+22.3%	$642.16M	$930K	N/A	131	News Coverage
ALT Altimmune	1.9077 of 5 stars	$3.27 +0.6%	$14.33 +338.3%	-30.5%	$632.18M	$40K	N/A	57

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. MNPR, SVA, NGNE, ALT, and CBIO

How does Humacyte compare to Monopar Therapeutics?

Summary

How does Humacyte compare to Sinovac Biotech?

Summary

How does Humacyte compare to Neurogene?

Summary

How does Humacyte compare to Altimmune?

Summary

How does Humacyte compare to Crescent Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. MNPR, SVA, NGNE, ALT, and CBIO

How does Humacyte compare to Monopar Therapeutics?

Does the media prefer MNPR or HUMA?

Which has preferable valuation & earnings, MNPR or HUMA?

Is MNPR or HUMA more profitable?

Do institutionals and insiders hold more shares of MNPR or HUMA?

Which has more volatility and risk, MNPR or HUMA?

Do analysts prefer MNPR or HUMA?

Summary

How does Humacyte compare to Sinovac Biotech?

Which has stronger earnings & valuation, HUMA or SVA?

Do analysts prefer HUMA or SVA?

Is HUMA or SVA more profitable?

Which has more volatility & risk, HUMA or SVA?

Do institutionals & insiders believe in HUMA or SVA?

Does the media favor HUMA or SVA?

Summary

How does Humacyte compare to Neurogene?

Which has higher earnings and valuation, HUMA or NGNE?

Which has more volatility and risk, HUMA or NGNE?

Do analysts rate HUMA or NGNE?

Does the media favor HUMA or NGNE?

Do institutionals and insiders believe in HUMA or NGNE?

Is HUMA or NGNE more profitable?

Summary

How does Humacyte compare to Altimmune?

Do institutionals & insiders hold more shares of HUMA or ALT?

Is HUMA or ALT more profitable?

Which has preferable valuation & earnings, HUMA or ALT?

Which has more volatility & risk, HUMA or ALT?

Do analysts rate HUMA or ALT?

Does the media favor HUMA or ALT?

Summary

How does Humacyte compare to Crescent Biopharma?

Which has more volatility and risk, CBIO or HUMA?

Does the media prefer CBIO or HUMA?

Is CBIO or HUMA more profitable?

Do insiders and institutionals believe in CBIO or HUMA?

Which has preferable earnings & valuation, CBIO or HUMA?

Do analysts rate CBIO or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools